Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Leniolisib · Joenja, CDZ-173

Small molecule · Inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) (PIK3CD) · developed by Pharming

Approved FDA, Mar 2023
PHAR Developer
2 Registered trials

What is Leniolisib?

Leniolisib is a small-molecule kinase inhibitor that blocks the active site of PI3K-delta, selectively over other PI3K isoforms. It reduces PI3K-delta-driven PIP3 signaling and mTOR/Akt hyperactivity, normalizing B and T cell dysregulation. It is studied in activated PI3K-delta syndrome (APDS).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Joenja, CDZ-173, CDZ-173-AZ
Drug type
Small molecule
Targets
phosphoinositide 3-kinase delta (PI3K-delta) (PIK3CD)
Mechanism
Inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) (PIK3CD)
Pathways
PI3K/Akt/mTOR, PIP3 production, B and T cell activation and proliferation
Therapy area
Immunology
Developer
Pharming (PHAR)
FDA status
Approved as Joenja (March 24, 2023), NDA217759 · FDA label
UNII
3700M1H39Q

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05438407 Phase 3 APDS Active not recruiting PHAR
NCT02859727 Phase 2/3 Activated PI3Kdelta Syndrome (APDS); PASLI Disease Terminated PHAR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

APDSActivated PI3Kdelta Syndrome (APDS); PASLI Disease

Other drugs acting on PIK3CD

More from Pharming

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.

Follow PHAR, the company behind Leniolisib

See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHAR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.